These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18047548)

  • 1. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
    Trossaërt M; Regnault V; Sigaud M; Boisseau P; Fressinaud E; Lecompte T
    J Thromb Haemost; 2008 Mar; 6(3):486-93. PubMed ID: 18047548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
    Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
    Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
    Ninivaggi M; Dargaud Y; van Oerle R; de Laat B; Hemker HC; Lindhout T
    J Thromb Haemost; 2011 Aug; 9(8):1549-55. PubMed ID: 21605333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis of non-severe hemophilia A phenotype with A discrepancy between one-stage and chromogenic factor VIII activity assays.
    Valikhani A; Mirakhorly M; Namvar A; Rastegarlari G; Toogeh G; Shirayeh FV; Ahmadinejad M
    Transfus Apher Sci; 2021 Oct; 60(5):103194. PubMed ID: 34275734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays.
    Duncan EM; Rodgers SE; McRae SJ
    Semin Thromb Hemost; 2013 Apr; 39(3):272-82. PubMed ID: 23460037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged α-thrombin-related activation and delayed active protein C-associated degradation confer mild phenotype in a patient with severe hemophilia A with F8 p.H118R.
    Miyashita R; Shinozawa K; Inaba H; Amano K; Kinai E
    Int J Hematol; 2022 Oct; 116(4):489-499. PubMed ID: 35590009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancy between the results of one-stage and chromogenic factor VIII: C assays in patients with mild/moderate hemophilia A.
    Vosough F; Ahmadinejad M; Toogeh G; Karimi K; Homayoun S; Managhchi MR; Arabkhazaeli A
    Blood Coagul Fibrinolysis; 2020 Dec; 31(8):530-535. PubMed ID: 33141777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
    Pezeshkpoor B; Gazorpak M; Berkemeier AC; Singer H; Pavlova A; Biswas A; Oldenburg J
    Ann Hematol; 2019 Aug; 98(8):1855-1865. PubMed ID: 30997536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics and Hemostatic Potential in Persons with Mild to Moderate Hemophilia A with a Discrepancy between One-Stage and Chromogenic FVIII Assays.
    Strålfors A; Mikovic D; Schmidt D; Onelöv L; Soutari NMH; Berndtson M; Chaireti R; Holmström M; Antovic JP; Bruzelius M
    Thromb Haemost; 2021 Jan; 121(1):27-35. PubMed ID: 32791533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
    Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
    Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity.
    Trossaërt M; Boisseau P; Quemener A; Sigaud M; Fouassier M; Ternisien C; Lefrançois-Bettembourg A; Tesson C; Thomas C; Bezieau S
    J Thromb Haemost; 2011 Mar; 9(3):524-30. PubMed ID: 21166991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.
    Santagostino E; Mancuso ME; Tripodi A; Chantarangkul V; Clerici M; Garagiola I; Mannucci PM
    J Thromb Haemost; 2010 Apr; 8(4):737-43. PubMed ID: 20102490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.
    Bowyer AE; Van Veen JJ; Goodeve AC; Kitchen S; Makris M
    Haematologica; 2013 Dec; 98(12):1980-7. PubMed ID: 23812942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
    Yada K; Nogami K; Wakabayashi H; Fay PJ; Shima M
    Thromb Haemost; 2013 Jun; 109(6):1007-15. PubMed ID: 23467620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.
    Cid AR; Calabuig M; Cortina V; Casaña P; Haya S; Moret A; Cabrera N; Aznar JA
    Haemophilia; 2008 Sep; 14(5):1049-54. PubMed ID: 18540892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements.
    Trossaert M; Lienhart A; Nougier C; Fretigny M; Sigaud M; Meunier S; Fouassier M; Ternisien C; Negrier C; Dargaud Y
    Haemophilia; 2014 Jul; 20(4):550-8. PubMed ID: 24517184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
    Bowyer AE; Kitchen S; Ezban M
    J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.